ProduitIndicationCollaborationPrécliniquePhase IPhase II



One patient, one cancer, one vaccine

With TG4050, Transgene is developing an individualized immunotherapy based on multiple advanced genetic engineering technologies and cutting-edge artificial intelligence capabilities, together with NEC.

Each treatment is based on an optimized viral vector, that is customized and manufactured for each patient. It integrates the most relevant tumor targets (patient-specific neoantigens) selected by NEC’s AI.

Once injected into the patient, the vaccine aims to inducing a specific immune response, enabling individualized targeted destruction of tumor cells. Two clinical trials are including patients in the USA, in the UK and in France. myvac® video
More information



Target HPV-induced cancers (HPV-16, E6 & E7 + IL-2)

TG4001, an innovative therapy capable of combating papillomavirus-induced cancers. The concept behind TG4001 is to teach the immune system to recognise and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7 antigens.

We have selected typical papillomavirus sequences that code for these antigens and have incorporated them into the DNA of a viral vector (MVA). We have also introduced a gene that codes for a molecule (interleukin 2, IL-2) that will stimulate the immune system at the injection site.

TG4001 triggers a specific immune response that supports the recognition and destruction of cancer cells carrying the HPV viral antigens. This approach enables the body to destroy the tumours.

Based on promising Phase Ib/II data, Transgene is conducting a randomized Phase II trial of TG4001 in combination with avelumab. This study is being conducted with the alliance of Merck KGaA, Darmstadt, Germany, which is supplying avelumab.

TG4001 in action

More information



Induce an immune response against tumors resistant to available treatments

TG6050 is an oncolytic virus that has been engineered to express human IL-12 and an anti-CTLA4 antibody. TG6050 has been designed to be administered intravenously.

By selectively targeting tumor cells and expressing IL-12 and an anti-CTLA4 antibody in the tumor microenvironment, TG6050 is expected to elicit a powerful and multi-pronged antitumor response.

Discover how TG6050 works

More information


BT-001 is the first oncolytic virus from Invir.IO™ and is optimized to act as a Trojan horse.

This novel immunotherapy approach has been designed to be highly targeted and is based on the patented viral backbone (VVcop TK-RR-). Two specific “weapons” have been integrated into the Vaccinia viral DNA: an anti-CTLA4 antibody, which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune response.

Once injected into the tumor, BT-001 replicates in the cancer cells leading to their targeted destruction by oncolysis and generating local production of its two therapeutic weapons. The resulting anti-CTLA4 antibody produced in the tumor neutralizes the regulatory T-cells that inhibit the immune system, thereby activating the immune defenses within the tumor itself.

The destruction of cancer cells also triggers an immune cascade that will enable the body’s systemic immune system to fight the tumour and its metastases. BT-001, given its multiple modes of action, could be developed to combat many different types of cancers.

Phase I/IIa clinical trial is enrolling patients in France and in Belgium; it has been granted an IND by the US FDA.

Public Information (ENNLFR)

BT-001 in action

More information

*IV: voie intraveineuse – *IT : voie intratumorale